Innovative Formulations in Neurodegenerative Pharmacology: From Nano emulsions to Controlled Release Technologies

Vinothini V, Vishnu priya T.R.M, Hadiya begum S

Bharath institute of higher education and research, Chennai-600073

Corresponding author: Vishnu Priya T.R.M
Email: vishnupriyatrm@gmail.com
Doi: **10.5281/zenodo.17596831**
Received: 25 August 2025
Accepted: 16 September 2025

Abstract
Neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) present formidable challenges for pharmacotherapy, largely due to the restrictive blood-brain barrier (BBB) [1]. Traditional small molecule drugs often fail to reach the therapeutic concentrations in the brain, necessitating novel delivery approaches. Cutting edge nanoscale formulations-including nanoemulsions, dendrimers, and controlled-release implants are being engineered to enhance CNS targeting and drug bioavailability. These platforms can bypass or exploit BBB transport pathways (e.g. receptor- mediated or intranasal routes) and enable sustained release, higher payloads, and targeting ligands for disease specific tissues [2]. This review provides a comprehensive overview of BBB transport mechanisms, formulation technologies, and their applications in ND therapy. We highlight specific examples (e.g. dopamine-loaded albumin/PLGA nanoparticles in PD or NO-releasing liposomal systems in AD) and discuss challenges in translation (toxicity, immunogenicity, scale-up) and future directions for personalized neurotherapeutics.

Keywords: neurodegenerative disease, drug delivery, Blood-brain barrier, nanoemulsions, liposomes, polymeric nanoparticle, controlled release.

Introduction

Neurodegenerative diseases (NDs) such as AD, PD, and ALS affect millions worldwide, with no curative therapies to date. A central obstacle to treatment is the BBB- a highly selective endothelial interface that excludes ~98% of small-molecule drugs and virtually all bio therapeutics. For example, lipid-soluble compounds smaller than ~400-600 Da may cross by passive diffusion, but most CNS drugs exceed this threshold. Conventional therapies (e.g. cholinesterase inhibitors or levodopa) thus show limited brain uptake and systemic side effects. Advances in nanomedicine and bioengineering are creating novel drug carriers that can transverse the BBB and deliver payloads to neural targets. Nanoparticles can be surface modified with targeting ligands (transferrin, peptides) or engineered for receptor-mediated transcytosis, adsorptive endocytosis, or even intranasal olfactory transport to reach the CNS. These innovations aim to improve pharmacokinetics (e.g. longer half-life, sustained release) and reduce peripheral toxicity. Here, we examine the mechanisms of brain drug delivery, review the latest formulation platforms (from nanoemulsions to biodegradable implants), and discuss their applications in AD, PD, ALS. We also outline key challenges (physiological barriers, manufacturing, and safety) and future trends (personalized nanocarriers, stimuli-responsive systems, gene delivery) in neuropharmacology.

Mechanisms of drug delivery

The BBB's tight junctions and efflux transporters prevent most drugs from entering the brain. Paracellular diffusion is negligible for drugs, so specialized pathways must be exploited. Major routes include receptor-mediated transcytosis (e.g. via transferrin, insulin, or low density lipoprotein receptors), adsorptive-mediated transcytosis (using cationic surfaces to bind endothelial cells), and carrier-mediated transport (for glucose, and amino acids). Cell-mediated delivery (Trojan horses using monocytes or stem cells) and physical disruption (focused ultrasound opening tight junctions) are emerging strategies. Intranasal administration provides another mechanisms: formulations deposited in the nasal cavity can travel along olfactory or trigeminal nerves directly into the CNS, bypassing the BBB. These nasal pathways have been used successfully with nanoemulsions and nanosuspensions for brain targeting. In all cases, optimizing particle size, charge, and ligand decoration is critical to exploit these transport mechanisms while avoiding rapid clearance. For example, nanoparticles ~50-200 nm can leverage transcytosis without inducing capillary occlusion [3].



Figure 1. Schematic of blood–brain barrier transport mechanisms. The BBB restricts >98% of drugs, so advanced carriers exploit multiple routes: (a) Paracellular diffusion (tight junctions), (b) trans cellular passive diffusion of lipid-soluble drugs, (c) receptor-mediated transcytosis (ligand-receptor binding), (d) adsorptive-mediated uptake (cationic interaction), (e) efflux pumps (p-glycoprotein) actively eject drugs

Table 1 represents Comparison of key delivery system

System	Size	Composition	Brain-Delivery Strategy	Release Profile	Example Application
Nano emulsion (O/W)	50–300 nm	Oil + surfactant + water	Intranasal or IV; can incorporate mucoadhesive surfactants	Fast release from droplets; modifiable for mucoadhesion	Brain-targeted delivery of hydrophobic drugs (e.g. curcumin, AchE inhibitors)

Liposome	50–200 nm	Phospholipid bilayer	Receptor-mediated (ligands on surface); PEGylation prolongs circulation	Can be made pH/thermo-responsive; controlled by lipid composition	Vaccine and antibody delivery; experimental AD therapies (antibody–liposome conjugates)
Polymeric NP (e.g. PLGA)	50–300 nm	Biodegradable polymer core	Surface ligands or cell-penetrating peptides; controlled degradation provides release	Sustained release over days-weeks	PD therapy (dopamine NPs); gene/drug co-delivery
SLN/NLC	50–300 nm	Solid lipid core + surfactant	Passive diffusion or endocytosis; improved stability over emulsions	Controlled release; lipophilic drug entrapment	Antioxidant delivery for AD/ALS
Dendrimers	<10 nm	Branched polymer (e.g. PAMAM)	Decoratable surface (multivalent ligands); penetrative bioavailability	Fast initial release, multiple attachment sites	Potential for siRNA/ASO delivery; experimental targeting
Hydrogel/In-situ depot	N/A (macro)	Crosslinked polymer matrix	Local implantation near CNS (e.g. Intrathecal)	Long-term sustained (weeks- months)	Chronic infusion of growth factors or chemokine
Micro needle/ Implant	100–500 µm	Silicones, metals (implantable pumps)	Bypasses GI; direct CNS infusion possible	Programmable dosing; very sustained	Experimental devices (e.g. L-DOPA infusion pump)

Table 2 represents Comparative analysis of drug delivery systems

Delivery System	**Advantages**	**Limitations**	**Clinical Status**
Nanoemulsions	High solubility, BBB penetration	Stability issues	Preclinical
SLNs	Controlled release, biocompatibility	Limited drug loading	Clinical trials
NLCs	Enhanced loading, stability	Complex formulation	Preclinical
Liposomes	Versatility, targeted delivery	Rapid clearance	Approved

Exosomes	Natural targeting, low immunogenicity	Production challenges	Research stage
FUS	Non-invasive BBB opening	Requires imaging guidance	Clinical trials
CED	Direct brain delivery	Invasive procedure	Clinical trials

Advances in Formulation technologies Nanoemulsions

Nanoemulsions are oil-water emulsions with droplet sizes typically in the 100-300 nm range, stabilized by surfactants. They combine the advantages of colloidal systems (high surface area, thermodynamic stability) with enhanced solubilization of lipophilic drugs. Crucially for ND, nanoemulsions can be formulated for intranasal (nose to brain) delivery, directly targeting the CNS while avoiding first-pass metabolism. For example, nasal nanoemulsions of neuroprotective agents have shown high brain uptake and efficacy in animal models, leveraging the trigeminal and olfactory pathways. The tiny droplets provide intimate contact with the mucosa and can be engineered for mucoadhesion or enzyme-triggered release. Key challenges are ensuring long-term stability and preventing drug expulsion into the continuous phase.

Nanoemulsions are submicron-sized emulsions with droplet sizes ranging from 20 to 200 nm. They are thermodynamically stable and have shown great promise in enhancing the solubility and bioavailability of lipophilic drugs. Their small size enables better penetration through the BBB and improved uptake by neuronal cells [4]. In the context of neurodegenerative diseases, nanoemulsions have been investigated for delivering drugs as curcumin, resveratrol, and rivastigmine, which suffer from poor water solubility and limited brain bioavailability [5]. These formulations have shown significant improvements in drug loading, controlled release, and pharmacokinetic profiles. For example, curcumin-loaded nanoemulsions demonstrated enhanced antioxidant and anti-inflammatory effects in animal models of Alzheimer's disease [6]. Similarly, nanoemulsions loaded with rivastigmine have shown prolonged release and better CNS accumulation compared to conventional formulations [7].

Nanoparticles

Nanoparticles, typically ranging from 1 to 1000 nm in size, are widely explored for their versatility in encapsulating various drugs and targeting CNS. Their surface can be modified with ligands to facilitate receptor-mediated transport across the BBB [8]. Polymeric nanoparticles, especially those made from poly (lactic-co-glycolic acid) (PLGA), have been extensively used for neuroprotective agents. For instance, PLGA nanoparticles loaded with dopamine or levodopa show sustained drug response and reduced degradation in systemic circulation [9]. Metal-based nanoparticles such as gold and selenium have also been studied

for their inherent neuroprotective properties. Gold nanoparticles conjugated with peptides or antibiotics have demonstrated targeted delivery to amyloid plaques in Alzheimer's models [10]. However, concerns regarding long-term toxicity and immunogenicity of some nanoparticle systems remain, warranting further investigation before clinical translation.

Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and lipophilic drugs. They have been used as brain-targeted delivery vehicles due to their biocompatibility and modifiability [11]. In neurodegenerative pharmacology, liposomes are often modified with targeting ligands such as transferrin or Apo lipoprotein E to enhance BBB permeability. For instance, transferrin-modified liposomes loaded with donepezil showed improved cognitive outcomes in animal models of Alzheimer's disease [12]. Furthermore, stealth liposomes coated with polyethylene glycol (PEG) demonstrate prolonged circulation time and reduced immune recognition, increasing the likelihood of reaching the CNS [13].

Liposomes are spherical vesicles composed of lipid bilayers encapsulating aqueous cores. They can carry both hydrophilic (in core) and lipophilic (in bilayer) drugs. Liposomes are biocompatible and have been widely

used in oncology (e.g. liposomal doxorubicin). For brain delivery, liposomes can be surface-decorated with targeting moieties (e.g. covalent attachment of peptides or antibodies against BBB transport receptors) [14]. Some liposomal systems have been engineered to respond to external stimuli (pH, temperature, ultrasound, or magnetic field) for controlled release [15]. For instance, thermo- or ultrasound-sensitive liposomes can release cargo in situ when externally activated. Liposomes flexible structure allows inclusion of stealth polymers (PEGylation) to prolong circulation. However, liposomes can be rapidly cleared by the reticuloendothelial system and may leak drugs if not stabilized.



Figure 2. Cross-sectional illustration of a stealth liposome (phospholipid bilayer in grey, hydrophilic head groups in white) used for drug delivery. Liposomes can carry hydrophilic drugs in their aqueous core and integrate hydrophobic drugs in the lipid bilayer. Surface PEGylation (blue corona) or ligand attachment enables prolonged circulation and receptor targeting

Polymeric nanoparticles

Polymeric nanoparticles (PNPs) are solid colloidal particles (often made from biodegradable polymers such as PLGA, polylactic acid, or chitosan) that encapsulate drugs within polymer matrix. PNPs can be engineered for controlled release: the polymer degrades slowly to release payload over days to weeks. They can also be surface-modified with PEG or targeting ligands to enhance BBB transit. In CNS applications, PNPs have encapsulated diverse molecules (small drugs, peptides, nucleic acids) and shown promise in delivering them deep into the brain tissue. For example, PLGA nanoparticles loaded with dopamine or growth factors have been used to replenish neurotransmitters in PD models. Advantages include high stability in circulation and tunable release kinetics. However, fabrication must avoid toxic solvents, and polymer degradation by-products must be non-inflammatory.

Dendrimers

Dendrimers are highly branched, nanoscale macromolecules that offer precise control over drug loading and release. They exhibit a high degree of surface functionality, making them suitable for targeting specific for targeting receptors in the CNS [16]. Poly (amidoamine) (PAMAM) dendrimers have shown significant promise in treating Alzheimer's and Parkinson's disease. For example, dendrimers-based delivery of N-acetyl cysteine has demonstrated neuroprotective effects and reduced oxidative stress in multiple studies [17]. The

ability to conjugate imaging agents to dendrimers also opens avenues for theranostic applications, allowing simultaneous diagnosis and treatment.

Hydrogels

Hydrogels are three-dimensional, hydrophilic polymer networks capable of retaining large amount of water. They are emerging as promising vehicles for localized, sustained release of neuroprotective agents directly into the brain tissues [18]. Injectable thermo sensitive hydrogels can transition from liquid to gel at body temperature, enabling minimally invasive administration. These systems are particularly useful for post-surgical implantation or targeting specific brain regions [19]. For instance, hydrogel-based delivery of brain-derived neurotrophic factor (BDNF) has shown enhanced neuronal survival and regeneration in Parkinsonian models [20].

Solid lipid and other Nanocarriers

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are composed of lipids solid at body temperature, stabilized by surfactants. They combine features of liposomes and polymeric NPs: a solid matrix foe slow release and biocompatibility of lipids. SLNs have been explored for explored for brain delivery of antioxidants and neuropeptides. Dendrimers (branched polymers with many terminal groups) offer ultra-small size and multivalent ligand attachment, enabling tight control over pharmacokinetics. Micelles (self-assembled amphiphilic block-copolymers) and nanoemulsions similarly improve solubility of hydrophobic neurodrugs. Emerging carriers include exosomes (natural vesicles from cells) and virus-like particles for gene delivery. Importantly, many carriers naturally provide controlled and sustained release: “nanocarrier systems like liposomes, nanogels, dendrimers, and SLNs offer controlled and sustained release of therapeutic agents, enhancing bioavailability and reducing side effects” [21].



Figure 3. Schematic of nanoemulsions structures. (A) Oil-in-water (O/W) nanoemulsions with oil droplets (yellow) dispersed in continuous water phase (blue), stabilized by surfactants (dark structures). (B) Multiple emulsion (W/O/W) with aqueous core (grey) inside oil droplets. Such nanoemulsions can solubilize lipophilic drugs in the oil phase and target the brain via intranasal or intravenous routes.

Table 3 represents Key drug-delivery mechanisms for Brain targeting

Controlled release technologies

Controlled release systems aim to maintain consistent therapeutic drug levels over an extended period,

Mechanism	Description	Examples	Advantages	Limitations
Passive Diffusion	Lipophilic small molecules cross BBB via transcellular route	Diazepam, L-DOPA	Simple, no carrier needed	Limited to small, non- polar drugs
Receptor-Mediated Transcytosis (RMT)	Ligand binds to endothelial receptors, initiating endocytosis and transport	Transferrin, insulin, lactoferrin-conjugated nanoparticles	High specificity, potential for targeting	Saturable, receptor expression may vary
Adsorptive-Mediated Transcytosis (AMT)	Cationic carriers interact with negatively charged endothelial surfaces	Cationic liposomes, cell-penetrating peptides	Broad applicability, not receptor-dependent	Low specificity, risk of non-specific uptake
Carrier-Mediated Transport (CMT)	Utilizes endogenous nutrient transporters at BBB	Glucose-conjugated nanoparticles, amino acid mimetics	Effective for small polar drugs, utilizes natural transporters	Limited cargo capacity, risk of competition with native ligands
Cell-Mediated Delivery	Monocytes/macrophages carry drugs across BBB ("Trojan horse" method)	Drug-loaded immune cells	Can bypass BBB, useful for inflammatory brains	Complex, potential immunogenicity
Intranasal Delivery	Direct nose-to-brain delivery via olfactory/trigeminal pathways	Nanoemulsions, liposomes, solid lipid nanoparticles	Non-invasive, bypasses BBB, rapid CNS access	Limited drug quantity, mucosal clearance

minimizing the frequency of dosing and improving patient compliance. These include osmotic pumps, implantable devices, and biodegradable matrices. In the treatment of Parkinson's disease, continuous dopaminergic stimulation is essential to prevent motor fluctuations. Duodopa, a gel form of levodopa/carbidopa delivered via intestinal infusion, exemplifies this principle and has shown significant

clinical benefits [22]. Implantable polymers releasing glial cell line derived neurotropic factor (GDNF) and also under investigation for halting neuronal degeneration in Parkinson's disease models [23]. Microspheres and nanospheres made from PLGA have been used for encapsulating drugs like ropinirole and rotigotine, providing sustained plasma levels and reducing dosing frequency [24]. In addition to nanoparticle carriers, controlled-release implants and depots are gaining attention. These include biodegradable polymer micro particles (microspheres) or in-situ forming gels that release drugs over extended periods. For example, in-situ forming PLGA depots of rivastigmine (an AD drug) have been developed for sustained CNS delivery, potentially reducing dosing frequency. Microchip and pump-based implants (programmable release devices) can also provide long-term dosing of neurotrophic factors or neurotransmitters.



Figure 4. Schematic diagram of controlled drug release into the

Table 4 represents the Formulation Platforms for CNS Drug Delivery (Key Features

Formulation Platform	Structure/Description	Drug Types	Key Features	Advantages	Limitations
Nanoemulsions	Oil-in-water (O/W) or W/O/W systems stabilized by surfactants	Lipophilic drugs	Enhance solubility, fast absorption, intranasal delivery	Easy to formulate, high surface area, improved CNS targeting	Physicochemical instability, surfactant- related toxicity
Liposomes	Phospholipid bilayer vesicles with aqueous core	Both hydrophobic and hydrophilic drugs	Biocompatible, modifiable surface (e.g., PEG, ligands)	Dual drug encapsulation, BBB targeting via ligand attachment	Rapid clearance if unmodified, potential leakage
Polymeric Nanoparticles	Biodegradable polymers like PLGA forming solid spheres	Wide range (hydrophilic/hydrophobic)	Sustained release, customizable degradation rates	High encapsulation efficiency, FDA-approved polymers	Manufacturing complexity, initial burst release
Solid Lipid Nanoparticles (SLNs)	Solid lipid matrix at body temperature	Lipophilic drugs	Physical stability, controlled drug release	Biocompatibility, protection of labile drugs	Limited drug loading, potential for polymorphic transitions
Dendrimers	Highly branched, multivalent synthetic polymers	Various drug types and genes	Surface modifiable, multivalent binding, precise size control	High payload, controlled architecture	Costly synthesis, potential cytotoxicity
Controlled-Release Depots	Microparticles or implants for subcutaneous/intracranial delivery	Chronic CNS therapeutics	Long-acting dosing, minimal systemic exposure	Reduced dosing frequency, localized therapy	Invasive placement, limited reversibility

Applications in Neurodegenerative disorders Alzheimer's disease

AD is characterized by β-amyloid plaques, tau neurofibrillary tangles, neuroinflammation, and cholinergic deficits. Conventional drugs (e.g. donepezil, memantine) yield only symptomatic relief. Nano delivery strategies are targeting key AD pathologies. For instance, nanoparticles have been used to deliver AchE inhibitors more effectively and to carry αβ-targeting compounds across the BBB. One study engineered nanoparticles containing donepezil with a surface ligand (regadenoson) that modulated tight junctions to enhance brain penetration. These Regadenoson-NPs facilitated dopamine or Ach delivery and even release nitric oxide to activate neuroprotective signaling, showing improved cognition in AD models. Other approaches use liposomes or polymeric NPs decorated with Apo lipoproteins (e.g. ApoE or ApoA-I mimetics) to shuttle through low-density lipoprotein receptors at the BBB. In parallel, immunotherapy (anti- αβ antibodies) and antioxidant drugs (curcumin, resveratrol) are being reformulated into nanocarriers to boost brain uptake.

Parkinson's disease

PD results from loss of midbrain dopaminergic neurons, leading to dopamine deficiency and motor dysfunction. Standard therapy is oral levodopa (with carbidopa), which has poor bioavailability and systemic side effects. Advanced DDS aim to deliver dopamine or dopamine agonists directly to the brain in a controlled

fashion. A striking example is the delivery of dopamine using albumin-coated PLGA nanoparticles (ALNP-DA). These PLGA/albumin NPs crossed the BBB in a PD mouse model, restored striated dopamine levels and motor coordination to near-normal levels without the need for invasive surgery. Lipid based carriers (SLNs, liposomes) loaded with dopamine precursors or enzyme inhibitors (e.g. levodopa-NOs) have also investigated. Beyond neurotransmitters, ND carriers deliver neurotropic factors (e.g. GDNF) or gene therapies (AAV vectors) to the basal ganglia. Importantly, as noted above, "nanoparticles including lipid-based, polymeric, metallic, and carbon-based" have all shown potential in PD models [25], and "nanocarrier systems like liposomes, nanogels, dendrimers, and SLNs offer sustained release, enhancing bioavailability and reducing side effects" [26].



Figure 5. Drug-loaded polymeric nanocarriers for Parkinson's therapy (adapted from Monge-Fuentes et al.). (a) Albumin/PLGA nanoparticle encapsulating dopamine and a tracer dye. (b) Schematic of nanoparticle crossing the BBB via adsorptive interactions and releasing dopamine in the striatum. These NPs significantly improved motor function in PD mice, demonstrating effective CNS delivery.

Amyotrophic Lateral Sclerosis

ALS involves degeneration of motor neurons in the brain and spinal cord, with targets including excitotoxic glutamate pathways, oxidative stress, and protein aggregates (e.g. mutant SOD1). The only FDA-approved drugs (riluzole, edaravone) have limited efficacy partly due to poor CNS penetration. Recent studies encapsulate edaravone in nanosystems (polymeric, lipid, or hybrid nanoparticles) to enhance stability and brain delivery. For example, surfactant-stabilized polymeric NPs carrying edaravone have shown improved in-vitro release profiles. Intrathecal delivery of antisense oligonucleotides (e.g. tofersen for SOD1 mutation) is also approved strategy, but Nano formulations of ASOs or siRNA could simplify administration. Overall, these examples illustrate that advanced carriers can address the unique pathologies of each ND by improving drug localization and kinetics.

Table 5 represents Neurodegenerative disease targets and delivery strategies

Disease	**Pathological Targets**	**Therapeutic Agents**	**Formulation Strategies**	**Examples of Carriers**

Alzheimer's Disease (AD)	β - a m y l o i d plaques- Tau protein tangles- Loss of cholinergic neurons	AChE inhibitors- Antioxidants- Anti-Aβ antibodies	Targeted delivery to Aβ and tau- Scavenging oxidative species- Enhancement of cholinergic signaling	A β - t a r g e t e d immunoliposomes- AChE inhibitor-loaded polymeric NPs- A n t i o x i d a n t - l o a d e d nanoemulsions
Parkinson's Disease (PD)	Dopaminergic neuron loss- α-synuclein aggregation	Dopamine- L-DOPA- Anti-α-synuclein agents	Sustained dopamine release- Inhibition of α- synuclein aggregation	Dopamine-encapsulated PLGA NPs- L-DOPA-loaded microspheres- α-syn-targeted lipid NPs
Amyotrophic Lateral Sclerosis (ALS)	Glutamate excitotoxicity- Oxidative stress- SOD1 mutations	Riluzole- Edaravone- Antisense oligonucleotides (ASOs)	BBB-penetrating antioxidant carriers- Genetic targeting strategies using ASOs	Riluzole-loaded lipid NPs- Edaravone nanocarriers- ASO- loaded lipid nanoparticles targeting SOD1

Challenges and Future directions

Despite promising preclinical data, several hurdles remain. Physiologically, the BBB is not static; in disease states its permeability can change unpredictably, complicating delivery. Efflux transporters (e.g. P-glycoprotein) actively pump many drugs out of brain cells. Nanocarriers themselves may trigger immune reactions or accumulate in clearance organs (liver, spleen) necessitating careful design of size, charge and surface chemistry. Manufacturing scale-up is nontrivial: batch-to-batch consistency, sterilization, and excipient sourcing are bottlenecks. Regulatory pathways for complex biologic-nanoparticle therapeutics are still evolving, which can delay clinical translation. Additionally, neurodegenerative disease are heterogeneous and often diagnosed late; delivery systems must be personalized and timed appropriately, perhaps even used for prophylaxis in high-risk individuals. Future innovations aim to overcome these challenges. Multimodal strategies (combining carriers with focused ultrasound BBB opening) are under investigation. Stimuli-responsive nanoparticles (releasing

drug only in the acidic or enzyme-rich microenvironment of disease) could enhance specificity. Gene-editing (CRISPR) delivered by NPs offers radical therapeutic potential. Machine- learning algorithms are being applied to design optimal carrier structures. Moreover, advanced models (BBB "organ-on-a-chip", humanized animal models) are improving our ability to predict CNS delivery. Ultimately, integrating nanotechnology with neuroscience-for example, synapse-targeting ligands or regenerative scaffolds that release neurotrophic factors- may yield truly breakthrough therapies for NDs. While current advances in formulation science offer great promise, several challenges remain. Translational hurdles such as manufacturing scalability, long-term safety, and regulatory approval must be addressed. Personalized medicine approaches, leveraging genetic and biomarker data, could allow customization of drug formulations to individual patients, improving efficacy and reducing adverse effects. Next-generation delivery systems integrating nanotechnology with bio responsive elements- such as stimuli-responsive carriers activated by pH or enzymes-are being developed to enhance precision and control. Additionally, artificial intelligence and machine learning are being explored to optimize drug formulations and predict pharmacokinetics and more accurately [27]. Another promising frontier is the development of multifunctional systems capable of combining diagnostics and therapeutics (theranostics), enabling real-time monitoring of treatment response. Collaborative efforts among neuroscientist,

pharmacologists, and formulation scientists are crucial for accelerating the bench-to-bedside transition. Regulatory bodies must also adapt to the evolving landscape of nano and bioengineered therapeutics facilitate timely approvals without compromising safety. Finally, patient-centric design considering ease of administration, minimal invasiveness, and improved quality of life should remain at the core of all innovation in neurodegenerative pharmacology.



Figure 6. Clinical administration routes. Conventional delivery (e.g. intravenous injection shown) exposes drugs to systemic clearance and non-specific tissues. Advanced carriers and routes (intranasal, intracerebral, targeted nanoparticles) seek to direct therapy specifically to the CNS.

Conclusion

Innovative drug delivery systems such as nanoemulsions, nanoparticles, dendrimers, hydrogels, and controlled-release devices are revolutionizing the treatment of neurodegenerative disorders. These advanced formulations overcome traditional pharmacokinetic barriers, especially the BBB, and provide more targeted, efficient, and safer therapeutic options. Future research should focus on optimizing these systems for clinical application, addressing regulatory challenges, and developing personalized approaches. Through interdisciplinary collaboration and technological integration, the potential for these advanced formulations to transform neurodegenerative disease management is immense. These systems have the potential to revolutionize the neurodegenerative disease treatment by surmounting the BBB and enabling targeting, controlled therapy. Emerging formulations from nanoemulsions and liposomes to smart implants that offer compelling advantages in preclinical models [28]. However, realizing their promise will require addressing translational gaps: ensuring safety, large scale manufacturability, and demonstrating clinical efficacy. A multidisciplinary approach, bridging pharmaceutics, neuroscience, materials science, is essential. As carriers become more sophisticated (e.g. carrying multiple drugs, combining therapy with diagnostics), and as early disease biomarkers improve, we anticipate that CNS- targeted nanomedicine will play an increasingly major role in managing Alzheimer's, Parkinson's, ALS, and beyond. Continued research into BBB biology, carrier design, and clinical protocols is crucial to turn these innovations into tangible patient benefits.

References

1. Bisht, S. F. (2007, April 17). *Springer Nature Link*. Retrieved from Springer link: https://doi.org/10.1186/1477-3155-5-3
2. Bonferoni, M. C. (2019, February 17). *MDPI*. Retrieved from mdpi: https://doi.org/10.3390/pharmaceutics11020084
3. Débora B Vieira, L. F. (2016, October 18). *National Library of Medicine*. Retrieved from PubMed Central: https://doi.org/10.2147/IJN.S117210
4. Deep Diyuti Kumar, B. M. (2015, october 15). *Royal society of chemistry*. Retrieved from pubs.rsc.org: https://pubs.rsc.org/en/content/articlehtml/2015/fo/c5fo00924c
5. Di Wu, Q. C. (2023, May 25). *Signal transduction and targeted therapy*. Retrieved from nature:

https://doi.org/10.1038/s41392-023-01481-w

6. Giuseppina Bozzuto, A. M. (2015, Febrauary 02). *Taylor & Francis online*. Retrieved from tandfonline:https:/doi.org/10.2147/IJN.S68861
7. Gómez-Gaete, C.(2007, March1).*ScienceDirect* Retrieved from sciencedirect: https://doi.org/10.1016/j.ijpharm.2006.11.028
8. Kannan, S. P. (2013, March 13). *Mary Ann liebert, Inc*. Retrieved from liebertpub: https://doi.org/10.1089/jop.2012.0232
9. Khushwant S. Yadav, K. C. (2010, June 17). *Wiley Analytical Science*. Retrieved from Analyticalsciencejournal:https:/doi.org/10.1002/ddr.20365
10. Kimia Alizadeh, H. M. (2022, May 26). *Springer Nature Link*. Retrieved from springerlink: https://doi.org/10.1007/s11064-022-03625-w
11. Liqiang Hu, Y. T. (2023, June 29). *frontiers*. Retrieved from frontiersin: https://doi.org/10.3389/fcell.2023.1228679
12. Mak, K.-K. (2019, March). *ScienceDirect*. Retrieved rom sciencedirect: https://doi.org/10.1016/j.drudis.2018.11.014
13. N. A. Peppas, Y. H.-L. (2000, August 01). *Annual Reviews*. Retrieved from anuualreviews: https://doi.org/10.1146/annurev.bioeng.2.1.9
14. Nyholm, D. (2012, September). *ScienceDirect*. Retrieved from sciencedirect: https://doi.org/10.1016/j.parkreldis.2012.06.022
15. Pardridge, W. M. (2012, August 29). *Sage Journals*. Retrieved from journals.sagepub: https://doi.org/10.1038/jcbfm.2012.126
16. Patel, R. T. (2017, November 22). *Springer Nature Link*. Retrieved from Springer Link: https://doi.org/10.1007/978-3-319-70299-5_14
17. Prashant Kesharwani, R. K. (2014, October 18). *SpringerNature Link*. Retrieved from springer link: https://doi.org/10.1007/s11095-014-1549-2
18. Richard Grondin, Z. Z. (2002, October). *Oxford Academic*. Retrieved from academic: https://doi.org/10.1093/brain/awf234
19. Saraiva, C. (2016, August 10). *ScienceDirect*. Retrieved from sciencedirect: https://doi.org/10.1016/j.jconrel.2016.05.044
20. Shakeel, F. B. (2008, july 09). *Springer Nature Link* . Retrieved from springer link: https://doi.org/10.1186/1477-3155-6-8
21. Singh, D. (2015, January 23). *Taylor Francis online*. Retrieved from tandfonline: https://doi.org/10.3109/21691401.2015.1029622
22. Tiantian Yin, L. Y. (2015, october 1). *ScienceDirect*. Retrieved from sciencedirect: https://doi.org/10.1016/j.actbio.2015.06.035
23. Tiwari, G. (2012, June). *National Library Medicine*. Retrieved from PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC3465154/
24. Torchilin, V. P. (2005, February 01). *nature reviews drug discovery*. Retrieved from nature: https://doi.org/10.1038/nrd1632
25. Ulbrich, K. (2009, February). *ScienceDirect*. Retrieved from sciencedirect: https://doi.org/10.1016/j.ejpb.2008.08.021
26. Virendra Kumar Yadav, S. D. (2025, january 22). *National Library of Medicine*. Retrieved from PubMed Central:https:/doi.org/10.3389/fmed.2025.1535682
27. Yuan, B. (2022, November 05). *ScienceDirect*. Retrieved from sciencedirect: https://doi.org/10.1016/j.ijpharm.2022.122225
28. Zhikun Liu, Q. L. (2021, September 13). *ACS Publications*. Retrieved from pubs.acs.org: https://doi.org/10.1021/acs.jmedchem.1c01240